Streetbeat News

Price Targets

VTLE

Stifel analyst Derrick Whitfield has maintained a 'Buy' rating on Vital Energy (NYSE:VTLE) and raised the price target from $112 to $119.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 6:50 pm

SIMO

Craig-Hallum analyst Anthony Stoss maintains a 'Buy' rating on Silicon Motion Technology (NASDAQ:SIMO) but has lowered the price target from $120 to $106.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 6:47 pm

SQ

Jefferies analyst Trevor Williams maintains a Buy rating on Block (NYSE:SQ) and raises the price target from $80 to $90.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 6:44 pm

BKR

B of A Securities analyst Chase Mulvehill has maintained a 'Buy' rating on Baker Hughes (NASDAQ:BKR) and raised the price target from $38 to $40.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 6:42 pm

PTC

RBC Capital analyst Matthew Hedberg maintains an 'Outperform' rating on PTC (NASDAQ:PTC) and raises the price target from $158 to $165.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 6:38 pm

BANF

DA Davidson analyst Gary Tenner maintains a Neutral rating on BancFirst (NASDAQ:BANF) and raises the price target from $84 to $91.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 6:37 pm

HALO

HC Wainwright has initiated coverage on Halozyme Therapeutics Inc (NASDAQ:HALO) with a Buy rating and a price target of $61. The analysts highlight the potential of Halozyme's Enhanze technology in the $41.7 billion U.S. infusion therapy market. They also note the company's commercial product portfolio obtained through the acquisition of Antares Pharma and the development of drug-device combination products.

Portfolio Pulse from Vandana Singh

July 24, 2023 | 6:36 pm

NOW

RBC Capital analyst Matthew Hedberg maintains an Outperform rating on ServiceNow (NYSE:NOW) and raises the price target from $540 to $650.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 6:32 pm

OB

Needham analyst Laura Martin reiterated a Buy rating on Outbrain Inc. (NASDAQ:OB), raising the price target to $6.50 from $5.50. Martin projects a larger total addressable market for Outbrain, banking on the new Onyx platform. The Onyx platform is expected to attract new clients and command a premium revenue share. For Q2, the analyst expects revenues of $55 million. For FY23, Martin projects OB's revenues to grow 0.9% Y/Y to $237 million, with an EPS loss of ($0.18). FY24 revenues are projected to grow 15.6% to $274 million, with EPS of $0.03.

Portfolio Pulse from Nabaparna Bhattacharya

July 24, 2023 | 6:22 pm

MRK

NRIX

HC Wainwright analyst Robert Burns has lowered the price target for Nurix Therapeutics Inc (NRIX) from $53 to $33, citing higher operating expenses and a decrease in the terminal growth rate. This comes after Nurix presented clinical and preclinical data from its targeted protein degradation programs, NX-5948 and NX-2127. The analysts also compared Nurix's results with Merck & Co Inc's (MRK) BELLWAVE-001 trial results, noting that nemtabrutinib's response rate is highly encouraging.

Portfolio Pulse from Vandana Singh

July 24, 2023 | 6:14 pm